Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmTumor Lysis Syndrome

Interventions

DRUG

Pegloticase

Given IV

DRUG

Rasburicase

Given IV

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER